Ergomed Aktie - WKN: A117XM

Seite 1 von 5
neuester Beitrag:  04.08.22 14:09
eröffnet am: 06.10.15 09:41 von: youmake222 Anzahl Beiträge: 124
neuester Beitrag: 04.08.22 14:09 von: PeppaPig Leser gesamt: 38156
davon Heute: 14
bewertet mit 4 Sternen

Seite:  Zurück   1  |  2  |  3  |  4  |  5    von   5     
06.10.15 09:41 #1 Ergomed Aktie - WKN: A117XM
Ergomed Aktie

WKN: A117XM

ISIN: GB00BN7ZCY67


   Website§www.ergomedplc.com

 
Seite:  Zurück   1  |  2  |  3  |  4  |  5    von   5     
98 Postings ausgeblendet.
10.05.21 16:12 #100 Shire & Genzyme
Mark Enyedy Appointed to Board as Non-Executive Director

Mr Enyedy brings more than 25 years of senior leadership experience in the biopharmaceutical sector, including executive management, corporate development and legal roles, across multiple therapeutic areas with a focus on rare diseases and oncology. He is currently President and Chief Executive Officer and a Director of ImmunoGen, Inc., a publicly-traded biotechnology company, where he oversees strategy and operations. He is also a member of the Board of Directors of the Biotechnology Innovation Organization (BIO), the world's largest advocacy organisation representing the biotechnology industry in the US and globally.


Prior to ImmunoGen, Mr Enyedy served in various executive capacities at [b]Shire[/b] plc, including as [b]Executive Vice President and Head of Corporate Development[/b], a role in which he negotiated and integrated the multi-billion dollar acquisitions of NPS Pharmaceuticals and Dyax Corp. and oversaw the $32 billion combination with Baxalta, Inc. Mr Enyedy was also previously President of the Transplant, Oncology and Multiple Sclerosis division at [b]Genzyme[/b] Corporation, and under his leadership the division achieved revenue growth from under $10 million to more than $675 million in just seven years. He began his career as an attorney at Palmer & Dodge, a Boston-based law firm where his practice focused on representing biopharmaceutical, high technology, and energy companies in M&A, licensing, and financing transactions.

https://www.investegate.co.uk/ergomed-plc--ergo-/...105100700089974X/  
12.05.21 15:09 #102 European Mediscience Awards 2021
NEWS:  European Mediscience Awards 2021. Ergomed has been shortlisted for “Best Communication Award” and “Company of the Year”.

http://www.mediscience-event.co.uk/nominations-overview/  
14.05.21 23:12 #103 Notice of AGM and Annual Report
01.06.21 16:14 #104 M&A remains on the agenda with plenty of f.
M&A remains on the agenda with plenty of firepower

Ergomed has repeated on several occasions that it aims to expand via both organic top-line growth and M&A.

EdisonGroup: Ergomed Valuation: £683m or 1,400p/share

https://www.edisongroup.com/publication/...lar-2020-performance/29566  
10.06.21 20:44 #105 strong start to 2021
Ergomed sees earnings ahead of expectations as chairman highlights strong start to 2021
https://www.proactiveinvestors.co.uk/companies/...to-2021-951909.html  
13.06.21 10:34 #106 ahead
18.06.21 16:04 #107 Fonds stockt weiter auf
15.07.21 09:44 #108 Ergomed Webinar
ERGOMED WEBINAR - REGISTER NOW: With the webinar only 1 week away, make sure you register with the link below to join our expert speakers, Hyankova Jana and Marcela Fialova, as they guide you through Pharmacovigilance Agreements (PVAs).


https://www.bigmarker.com/...VL-WEBINAR-7-21-2021?show_live_page=true  
27.07.21 10:12 #109 revenue growth of 38.8%
Ergomed plc - Trading Update
+Total revenue growth of 38.8% over H1 2020 to £56.0 million (up 48.1% in constant currency*)

+CRO division delivered strong growth with revenue up 90.7% over H1 2020 to £27.2 million, including the MedSource business acquired in 2020, with like-for-like growth of 16.1% (24.5% in constant currency)

https://www.proactiveinvestors.co.uk/LON:ERGO/Ergomed-PLC/rns/1010148  
27.07.21 11:36 #110 exceptional first half performance
28.07.21 08:54 #111 Ergomed revenue jumps in first half amid new.
Ergomed revenue jumps in first half amid new business wins
https://www.stockmarketwire.com/article/7211145/...business-wins.html  
11.08.21 11:02 #112 Executive interview
12.08.21 10:52 #113 Momentum continues with EBITDA upgrades
28.09.21 08:19 #114 Ergomed Interim results
Ergomed Interim results


   Total revenue growth of 38.8% over H1 2020 to £56.0 million (up 48.1% in constant currency*)
    djusted EBITDA of £12.1 million up 33.0%
   Basic adjusted earnings per share of 16.8p, up 48.7%
   Service fee revenue growth of 29.3% (11.1% on a like-for-like basis, 18.2% in constant currency*)
   CRO revenue up 90.2% over H1 2020 to £27.2 million, with like-for-like growth of 16.1% (up 24.5% in constant currency*)
   Net new sales awards in H1 2021 increased by 50.8% over H1 2020
   Growth in order book maintained - up 18.0% since 1 January 2021 (£193.0 million) and up 50.5% on prior year to £227.8 million, providing high visibility into H2 2021 and beyond
   Continued international expansion with growing presence in the USA
   North America revenues up 70.8% to £35.5 million with recent acquisitions Ashfield Pharmacovigilance and MedSource fully integrated
   Cash balance increased to £24.6 million and debt free

https://www.proactiveinvestors.co.uk/LON:ERGO/Ergomed-PLC/rns/1039549  
29.09.21 10:22 #115 great progress on delivering on strategy
Ergomed reveal 'great progress on delivering on strategy in first half of 2021'
https://www.proactiveinvestors.co.uk/companies/...f-2021--961530.html  
04.10.21 15:02 #116 US is now the biggest market in the mix
US is now the biggest market in the mix

Ergomed has released its full H121 results. H121 revenue numbers were included in the trading update in July 2021, while the full accounts released last week provided details on profits. In the trading update, management also guided that FY21 adjusted EBITDA would be materially ahead of market expectations, which has since been discounted in the share price, hence last week’s announcement delivered no surprises. However, the key takeaway for us was that overall operational momentum continues to be strong, including the first three months of H221 (following the already stellar performance in FY20). In H121, Ergomed has also launched its expansion into the Japanese market. We have slightly increased our valuation to £751m or 1,536p/share (from 1,445p/share).

https://www.edisongroup.com/publication/...st-market-in-the-mix/30007  
11.10.21 11:24 #117 Vice President
Ergomed : Debra Kientop appointed as the new Vice President of Therapeutic Strategy for Oncology
https://www.marketscreener.com/quote/stock/...-for-Oncology-36596123/  
13.10.21 14:42 #118 Oncology
Navigating the Path Towards Decentralized Trials in Oncology: From Technology to AI", this hot topic webinar will occur on 18 November 2021.

https://www.bigmarker.com/...p;utm_campaign=november+2021+cro+webinar  
22.10.21 15:48 #119 Proactive One2One virtual forum
Ergomed (LON:ERGO) Presenting at the Proactive One2One virtual forum - October 2021 https://www.proactiveinvestors.co.uk/companies/...er-2021-964010.html  
07.11.21 11:50 #120 Gibt es auchDeutsche Beiträge ?
???  

Bewertung:

07.11.21 17:07 #121 Meist Englisch, da wenig bekannt in D
Soweit ich informiert bin, gibt es nur Edison, die Ergomed regelmäßig covern, aber diese Berichte sind auf Englisch - alle auf der Ergomed-Webseite zu finden.

Ich selbst bin vor ein paar Jahren über einen Artikel im Aktionär auf Ergomed aufmerksam geworden, aber das war 2019 und seitdem kam da auch nix mehr.

https://www.deraktionaer.de/artikel/...ie-rallye-weiter-20194148.html

Für aktuellere Artikel oder Meinungen wäre ich auch dankbar.
 

Bewertung:

15.11.21 11:25 #122 Ergomed to Present at Jefferies Conference 2.
07.01.22 12:25 #123 US is now the biggest market in the mix
04.08.22 14:09 #124 Berenberg startet Ergomed mit Buy
Seite:  Zurück   1  |  2  |  3  |  4  |  5    von   5     
Antwort einfügen - nach oben
Lesezeichen mit Kommentar auf diesen Thread setzen:    


Bitte warten...